This Hong Kong-based company used its AI platform, Pharma.AI, to design a novel drug candidate for idiopathic pulmonary fibrosis (IPF) in 18 months. The candidate, ISM001, has shown promising results in preclinical studies and is now entering Phase I clinical trials. This is a timeline previously un...